CLL Market Update: Imbruvica Leads Way, Jump-Started By Robust Launch
Recent BioMedTracker surveys suggest that most doctors are using new oral drugs – J&J/Pharmacyclics Imbruvica and Gilead’s Zydelig – generally in line with labeling, while uptake of Roche’s Rituxan-successor Gazyva is lower than expected.
You may also be interested in...
In addition to a spate of FDA approvals closing out the year, Roche contended with trial failures and Actavis received a “complete response” letter for its nebivolol/valsartan combination.
In a deal worth more than $800 million, AbbVie injects a vote of confidence into Infinity’s late-stage PI3K inhibitor program, but leaves the biotech the freedom to conduct other partnerships.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.